Skip Navigation
  • New Phase 2 trial results show promise for ALS
    Results of a new Phase 2 randomized clinical trial in 137 patients with ALS showed that treatment could significantly slow functional decline over 24 weeks compared to placebo.
  • Research Byte: Packard scientists identify new ALS-related protein quality control pathway
    In a new study, Packard researcher Jiou Wang and colleagues have identified a new regulatory switch for protein quality control that plays a role in the development of ALS.
  • Packard Center announces new Scientific Executive Committee
    The Packard Center is delighted to announce the appointment of Aaron Gitler, Ph.D., Piera Pasinelli, Ph.D., Sami Barmada, M.D., Ph.D. and Christopher Donnelly, Ph.D.
  • Packard awards grant to fund study of microglia in ALS/FTD
    This grant was made possible by a generous donation from The Bruce Edwards Foundation.

What is ALS?

Amyotrophic lateral sclerosis (ALS), also known as called Lou Gehrig's, disease is a rapidly progressive, fatal neurological disease that attacks the nerve cells (neurons) responsible for controlling voluntary muscles.  The average life span from diagnosis is two to five years.  There is no cure.

Understanding ALS

Join the Family - Get Involved

You can make a difference. Tell us your story. Get involved. Make a Gift.
The hope is in the science.